Enanta Pharmaceuticals (FRA:9EP) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EP Enanta Pharmaceuticals Inc FRA:9EP
55 GF Score
Price €10.60
GF Value €6.67
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enanta Pharmaceuticals  (FRA:9EP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.10 8.78 1.67 1.41 1.69

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.68 2.40 1.88 2.19

FRA:9EP vs LXEO, XFOR, GALT: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:9EP
55GF Score
Enanta Pharmaceuticals Inc FRA:9EP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Enanta Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.425/333.9520*333.9520
=0.425

Current CPI (Jun. 2026) = 333.9520.

Enanta Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.604 241.428 0.835
201612 0.507 241.432 0.701
201703 0.441 243.801 0.604
201706 0.358 244.955 0.488
201709 3.299 246.819 4.464
201712 1.625 246.524 2.201
201803 1.740 249.554 2.328
201806 2.287 251.989 3.031
201809 2.743 252.439 3.629
201812 2.943 251.233 3.912
201903 1.655 254.202 2.174
201906 1.871 256.143 2.439
201909 2.211 256.759 2.876
201912 2.286 256.974 2.971
202003 1.258 258.115 1.628
202006 0.846 257.797 1.096
202009 1.008 260.280 1.293
202012 1.325 260.474 1.699
202103 0.829 264.877 1.045
202106 0.889 271.696 1.093
202109 0.989 274.310 1.204
202112 1.186 278.802 1.421
202203 0.812 287.504 0.943
202206 0.883 296.311 0.995
202209 0.972 296.808 1.094
202212 1.111 296.797 1.250
202303 0.788 301.836 0.872
202306 0.824 305.109 0.902
202309 0.826 307.789 0.896
202312 0.794 306.746 0.864
202403 0.742 312.332 0.793
202406 0.788 314.175 0.838
202409 0.627 315.301 0.664
202412 0.749 315.605 0.793
202503 0.664 319.799 0.693
202506 0.756 322.561 0.783
202509 0.605 324.800 0.622
202512 0.556 324.054 0.573
202603 0.505 330.213 0.511
202606 0.425 333.952 0.425

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Enanta Pharmaceuticals (FRA:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €10.60 is trading 58.9% above its estimated GF Value™ of €6.67.

Key valuation signals for FRA:9EP:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €6.67 vs. price of €10.60 (58.9% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
55GF Score

Get the complete analysis for FRA:9EP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.60
Price
€6.67
GF Value